Skip to main content
Terug
HRMY logo

Harmony Biosciences Holdings, Inc.

Datakwaliteit: 100%
HRMY
NASDAQ Healthcare Biotechnology
€ 27,10
▼ € 0,50 (-1,81%)
Marktkapitalisatie: 1,57B
Dagbereik
€ 26,75 € 27,36
52-Weeksbereik
€ 25,52 € 40,87
Volume
1.058.372
50D / 200D Gem.
€ 33,21 / € 33,59
Vorige Slotkoers
€ 27,60

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 9,9 0,3
P/B 1,8 2,9
ROE % 20,8 3,7
Net Margin % 18,3 3,8
Rev Growth 5Y % 29,9 10,0
D/E 0,3 0,2

Koersdoel Analisten

Hold
€ 48,17 +77.7%
Low: € 31,00 High: € 62,00
Forward K/W
7,8
Forward WPA
€ 3,55
WPA Groei (sch.)
+0,0%
Omzet Sch.
1 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 4,53
€ 3,88 – € 4,95
 1,1 B 3
FY2029 € 5,17
€ 4,43 – € 5,65
 1,3 B 3
FY2028 € 4,87
€ 1,45 – € 6,48
 1,2 B 9

Belangrijkste Punten

Revenue grew 29,85% annually over 5 years — strong growth
ROE of 20,75% indicates high profitability
Net margin of 18,27% shows strong profitability
Debt/Equity of 0,28 — conservative balance sheet
Generating 347,89M in free cash flow
P/E of 9,88 — trading at a low valuation

Groei

Revenue Growth (5Y)
29,85%
Revenue (1Y)21,51%
Earnings (1Y)9,07%
FCF Growth (3Y)26,02%

Kwaliteit

Return on Equity
20,75%
ROIC14,09%
Net Margin18,27%
Op. Margin24,00%

Veiligheid

Debt / Equity
0,28
Current Ratio3,60
Interest Coverage14,23

Waardering

P/E Ratio
9,88
P/B Ratio1,80
EV/EBITDA5,06
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 21,51% Revenue Growth (3Y) 22,15%
Earnings Growth (1Y) 9,07% Earnings Growth (3Y) 10,97%
Revenue Growth (5Y) 29,85% Earnings Growth (5Y) 46,34%
Profitability
Revenue (TTM) 868,45M Net Income (TTM) 158,69M
ROE 20,75% ROA 12,48%
Gross Margin 77,16% Operating Margin 24,00%
Net Margin 18,27% Free Cash Flow (TTM) 347,89M
ROIC 14,09% FCF Growth (3Y) 26,02%
Safety
Debt / Equity 0,28 Current Ratio 3,60
Interest Coverage 14,23 Dividend Yield 0,00%
Valuation
P/E Ratio 9,88 P/B Ratio 1,80
P/S Ratio 1,80 PEG Ratio 1,74
EV/EBITDA 5,06 Dividend Yield 0,00%
Market Cap 1,57B Enterprise Value 1,05B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 868,45M 714,73M 582,02M 437,86M 305,44M
Net Income 158,69M 145,49M 128,85M 181,47M 34,60M
EPS (Diluted) 2,71 2,51 2,13 2,97 0,58
Gross Profit 670,11M 557,92M 460,79M 354,37M 249,92M
Operating Income 208,47M 190,83M 192,03M 120,19M 87,53M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,27B 999,20M 811,45M 673,87M 433,44M
Total Liabilities 401,41M 340,05M 344,46M 271,03M 246,94M
Shareholders' Equity 870,22M 659,16M 466,99M 402,84M 186,51M
Total Debt 239,58M 181,41M 193,57M 191,65M 195,74M
Cash & Equivalents 752,50M 453,00M 311,66M 243,78M 234,31M
Current Assets 907,01M 579,25M 451,07M 400,29M 284,44M
Current Liabilities 252,13M 175,08M 163,78M 78,88M 53,78M

Strategiescores

This stock passed the criteria for 6 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#294 of 1052
56
Custom Capital Light Compounder
#150 of 218
32
Custom Contrarian Investing (David Dreman)
#371 of 670
25
Value Value Investing (Warren Buffett)
#14 of 203
58
Custom Full Throttle
#99 of 146
35
Custom Balanced Risk
#62 of 151
48

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Capital Light Compounder
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Value Investing (Warren Buffett)
Mar 24, 2026
Ingestapt Full Throttle
Mar 24, 2026
Ingestapt Balanced Risk
Mar 24, 2026